Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Intermediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient Outcomes

International Journal of Radiation Oncology Biology Physics

Volumn 95, Issue 3, 2016, Pages 960-964

  Kotecha, Rupesh ^a   Djemil, Toufik ^a   Tendulkar, Rahul D ^a   Reddy, Chandana A ^a   Thousand, Richard A ^a   Vassil, Andrew ^a   Stovsky, Mark ^b   Berglund, Ryan K ^b   Klein, Eric A ^b   Stephans, Kevin L ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGENS; DISEASES; RADIOTHERAPY; RISK ASSESSMENT; TOXICITY; UROLOGY;

COMMON TERMINOLOGY CRITERIA; DIFFERENTIAL TREATMENT; GASTROINTESTINAL TOXICITIES; HIGH-RISK PROSTATE CANCERS; METHODS AND MATERIALS; NATIONAL CANCER INSTITUTE; PROSTATE SPECIFIC ANTIGEN; STEREOTACTIC BODY RADIATION THERAPY;

PATIENT TREATMENT;

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BIOCHEMICAL RECURRENCE; BLADDER; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DOSIMETRY; FOLLOW UP; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HUMAN; INTERMEDIATE RISK PATIENT; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE ESCALATION; RADIATION DOSE FRACTIONATION; RECTUM; RECURRENCE FREE SURVIVAL; SEMINAL VESICLE; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; URETHRA; ADULT; ADVERSE EFFECTS; AGED; CLINICAL TRIAL; COMPLICATION; GASTROINTESTINAL DISEASES; MIDDLE AGED; PILOT STUDY; PROCEDURES; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOSURGERY; RISK FACTOR;

ADULT; AGED; DOSE FRACTIONATION; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOSURGERY; RISK FACTORS; TREATMENT OUTCOME;

EID: 85009904416     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2016.02.009     Document Type: Article

References (7)

1. 1 King, C.R., Brooks, J.D., Gill, H., et al. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 82 (2012), 877–882.
2. 2 Boike, T.P., Lotan, Y., Cho, L.C., et al. Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol 29 (2011), 2020–2026.
3. 3 King, C.R., Freeman, D., Kaplan, I., et al. Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol 109 (2013), 217–221.
4. 4 Katz, A., Kang, J., Stereotactic body radiation therapy for low-, intermediate-, and high-risk prostate cancer: Disease control and quality of life at 6 years. Int J Radiat Oncol Biol Phys 87 (2013), S24–S25.
5. 5 Bauman, G., Ferguson, M., Lock, M., et al. A phase 1/2 trial of brief androgen suppression and stereotactic radiation therapy (FASTR) for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 92 (2015), 856–862.
6. 6 Kim, D.W., Straka, C., Cho, L.C., et al. Stereotactic body radiation therapy for prostate cancer: Review of experience of a multicenter phase I/II dose-escalation study. Front Oncol, 4, 2014, 319.
7. 7 Kim, D.W., Cho, L.C., Straka, C., et al. Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 89 (2014), 509–517.